Molecular Docking of Benzoylurea Derivatives as Potential Anti-Breast Cancer Agent and Its Admet Profiles

Siswandono Siswandono

Abstract

Objective: At present therapy for breast cancer leads to target cell therapy. One of the compounds that can be developed as anti-breast cancer agents is benzoylurea. Benzoylurea has the same pharmacophore group with hydroxyurea as urea derivatives which have anticancer activity. This study aims to predict the anticancer activity and ADMET profile of seven benzoylurea-derived compounds as candidates cytotoxic agent for breast cancer. Method: Biological activity of benzoylurea derivatives is predicted through molecular modeling (in silico) using the Autodock program, ADME profiles and toxicity can be predicted using the pkCSM program and the Protox II online tool. In silico test was carried out by docking between benzoylurea derivatives and HER2 receptor targets, PDB ID. 3PP0. Result: All benzoylurea-derived compounds studied were compliant with Lipinski's 5 legal requirements. The 4-tertier butylbenzoylurea compound shows a  better ADME profile and its toxicity is predicted to have mutagenic properties but not hepatotoxic properties. The smallest docking score of seven benzoylurea derivatives is 4-tertier butylbenzoylurea, therefore the compound has the best cytotoxic activity. Conclusion: the 4-tertier butylbenzoylurea compound is chosen as the compound to be synthesized and further developed.

Keywords : molecular docking; benzoylurea; anti-breast cancer; ADMET profiles

Full Text:

PDF

References

International Agency for Research on Cancer. World Health Organization. https://www.who.int/cancer/PRGlobocanFinal.pdf 2018; 2-3 (18 November 2019).

Siswandono. Medicinal Chemistry I. 2nd ed. Surabaya: Airlangga University Press; 2016.

Schlick, T. Molecular Modeling and Simulation : An Interdisciplinary Guide. 2nd ed. New York: Springer Science+Business Media; 2010.

Hinchliffe, A. Molecular Modeling for Beginners. 2nd ed. Chichester: John Wiley and Sons Ltd; 2008.

Jensen, F. Introduction to Computational Chemistry. 2nd ed. Chichester: John Wiley & Sons Ltd; 2007. p. 415-416.

Singh M, Jadhav HR. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discovery Today 2017.doi: https://doi.org/10.1016/j.drudis.2017.10.004.

Zulkifli AA, Tan FH, Putoczki TL, Stylli SS, Luwor RB. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Molecular and Cellular Endocrinology 2017; 451:15-23.

Alanazi IO, Khan Z. Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications. Asian Pac J Cancer Prev 2016;17(2): 445-453.

Li HQ, Yan T, Yang Y, Shi L, Zhou CF, Zhu HL. Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N’-phenylureas and thioureas as antitumor agents. Bioorganic & Medicinal Chemistry 2010;18(2010):305-313.

Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. ErbB2-mediated Src and STAT3 Activation Leads to Transcriptional Upregulation of p21Cip1 and Chemoresistance in Breast Cancer Cells. Mol Cancer Res 2009;7(4): 592-600.

Diyah NW, Siswandono, Hardjono S, Purwanto BT. Molecular Modeling and Quantitative Relationship of Structure - Cytotoxic Activity of Benzoilurea Derived as Antitumor. Berkala Ilmiah Kimia Farmasi 2013;2(2): 20-27.

Suhud F, Siswandono, Budiati T. Synthesis and Activity Test of 1-Benzyl-3-benzoylurea Compounds with Bromo, Kloro, Floro and Triflorometil substitution in para position as Antiproliferative Agent. Media Pharmaceutica Indonesiana 2017;1(3):154-163.

Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, et al. Structural Analysis of The Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein. J. Biol. Chem 2011;286(21):18756-18765.

National Cancer Institute. Online SMILES Translator. United States https://cactus.nci.nih.gov/translate/ (18 November 2019).

Pires DEV, Blundell TL & Ascher DB. The University of Melbourne’s pkCSM Small-molecule Pharmacokinetics Prediction. http://biosig.unimelb.edu.au/pkcsm/prediction/ (18 November 2019).

Charite University of Medicine-Institute for Physiology. ProTox-II-Prediction of Toxicity of Chemicals. http://tox.charite.de/protox_II/ (18 November 2019).

Kesuma D, Siswandono, Purwanto BT, Hardjono S. Cytotoxic Activity and Toxicity in silico of N-(Benzoyl)-N’-phenyltiourea Derived Compounds as Anticancer Drug Candidates. J.Pharm Sci Clin Res 2018;3(1):1-11.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv.Drug Deliv. Rev 1997;23(1-3):3-26.

Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting Small Molecule Pharmacokinetic and Toxicity Properties using Graph-based Signatures. J.Med.Chem 2015;58(9):4066-4072. DOI:1021/acs.jmedchem.5b00104.

Ekowati J, Diyah NW, Novianti KA, Hamid IS, Siswandono. Molecular Docking of Ferulic Acid Derivates on P2Y12 Receptor and their ADMET Prediction. J.Math.Fund.Sci 2018;50(2):203-219.

Yallowitz A, Garcia L, Alexandrova EM, MarchenkonN. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells. Cell Death and Disease 2018;9:621.

Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O’Leary P, Holmes FA, et al. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer 2018;18:965.

Refbacks

  • There are currently no refbacks.


Bookmark and Share